Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions Peter Hodson
Transition Therapeutics IncTTH.TOBUY ON WEAKNESSSep 24, 2004
A pretty decent company. Got smeared with the same brush as Conjuchem. Doesn't expect anything this year as it will probably be sold as a tax loss. OK for the long term.
Peter HodsonUnknown
$1.03
Stock price when the opinion was issued
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
BUY
In general, he does not like Biotech's but he likes this company a lot. Looking at introducing therapy into the Alzheimer's stage, which would be disease altering, which would reverse the effects. Have good US partners. Likes for the long term.
Hugh Cleland, CFAOwned
biotechnologypharmaceutical
BUY
In diabetes, but their big upside now is in their Alzheimer’s work. Their therapy is the only one that could be disease changing, not just the symptoms. It will take 5-7 years to prove it out.
Hugh Cleland, CFAOwned
biotechnologypharmaceutical
STRONG BUY
Generally stays away from pure biotech. Interesting diabetes play, but likes it for the Alzheimer’s play. Has a drug that could be disease altering as opposed to symptom altering. It’ll be years before it comes through as a drug, but if it does, sales will be massive.
Hugh Cleland, CFAOwned
biotechnologypharmaceutical
BUY
Has been consolidating around the $1 for some time. Seeing some selling pressures re: warrants that were converted. A relatively high risk name, but if they are successful across one or two of the different platforms they have, stock could be significantly higher. Good management team.
biotechnologypharmaceutical
BUY
Has a few products, but has one primary product in diabetes. If he gets it right, and the animal studies come through in humans, thinks the stock will go from $1 to over $10. The good news is that it has 2/3 other products coming up behind it, so if it drops, will only go down to $0.50.
Hugh McCauleyOwned
biotechnologypharmaceutical
BUY
Best to own a basket when owing smaller bio techs. Gigh risk/high return. Their diabetes drug, if it flows through, has a huge market potential. News flow has been fairly good. Still early stage. Good management.
Mark Jackson, CFAOwned
biotechnologypharmaceutical
TOP PICK
Biotech world has had a tough time in the last month. This company is progressing well. Will take over the clinical development which is very lucrative for the company. Likes management and their pipeline.
Ed HoOwned
biotechnologypharmaceutical
TOP PICK
Has an interesting pipeline of products. An early stage product is a diabetes treatment.
Ed HoOwned
biotechnologypharmaceutical
BUY
Have the best animal model data that he has ever seen. If they can make the transition to human models, the stock would go to $10. Results could be out by the end of this year or the beginning of next.
Hugh McCauleyOwned
biotechnologypharmaceutical
